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Abstract
In this study, we developed a series of synthetic oligonucleotides that allowed us to investi-
gate the details on the antigen recognition by autoimmune antibodies in localized sclero-
derma subjects. Besides dramatically improved analytical specificity of the assay, our data
suggests a potential linking for antibodies to DNA to the biological status of disease state in
localized scleroderma. Moreover, introducing chemical modifications into short synthetic
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules completely changed
the binding titers of corresponding antibodies and their clinical relevance. The strongest
observed effect was registered for the localized scleroderma skin damage index (LoSDI) on
the IgG antibodies to TC dinucleotide-rich double-stranded antigen (p < 0.001). In addition
to providing valuable tools for diagnosis of clinically relevant biomarkers, we believe that this
work opens up new opportunities for research on antibodies to nucleic acids in localized
scleroderma and other autoimmune diseases.
Introduction
Localized Scleroderma (LS) is an autoimmune disease characterized by hardening of the skin
with subsequent atrophy, and typically in childhood onset this occurs in linear bands along the
lines of Blaschko. It frequently affects the underlying subcutis, fascia, bones and muscles,
resulting in growth defects, especially in childhood onset disease [1, 2]. The diagnosis of LS,
also termed morphea, is typically delayed due to its under-recognition and misdiagnosis, with
an average delay of disease onset to diagnosis of 12 months [2, 3]. Diagnosis is usually made by
a physician more familiar with the condition, a dermatologist or rheumatologist, and may be
augmented by the performance of a skin biopsy. The histological examination of the skin dem-
onstrates edematous changes in collagen and the presence of a lymphoplasmacytic infiltrate in
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the dermis, perivascular and peribulbar/eccrine glands during the early phase, and hyaliniza-
tion of collagen with loss of skin appendages in later stages of LS [1, 3].
Although the pathogenesis of LS remains unclear, there is evidence supporting it as an
autoimmune disease, including a positive auto-antibody profile, concurrent associated auto-
immune diseases (vitiligo and arthritis), and family history of autoimmune disease [4]. Auto-
antibodies, which are commonly identified in LS patients include antinuclear antibodies
(ANA), anti-single-stranded deoxyribonucleic acid antibody (anti-ssDNA Ab), and anti-his-
tone antibody (AHA) [5].
There are no diagnostic laboratory tests for LS but there is a high prevalence of autoanti-
bodies including ANA, which could be supportive of the diagnosis [5]. According to the litera-
ture, a positive ANA is found in 42 to 73% of LS subjects and has been associated with an
increased risk for disease complications [6, 7]. The prevalence of ss-DNA and AHA in LS is
approximately 50% [8] and both are associated with disease severity features, such as deep
muscle involvement, joint contractures and increase number of lesions [7, 9].
Today, patients suspected with LS are offered ANA, anti-single-stranded deoxyribonucleic
acid (anti-ssDNA) and anti-histone tests. For more than 50 years, the immunofluorescent
ANA test has been the “gold standard” in the identification of autoimmune disease [6, 10].
When positive in LS patients, ANA has been associated with early disease, increased risk of
extra cutaneous manifestations [7, 11] and predictor of flare in LS [12]. However, “the gold
standard” lacks specificity as it provides a high frequency of serological positivity related to
many other conditions [10, 13]. In LS, anti-ssDNA and anti-histone antibodies are correlated
with each other and are associated with more severe disease, as defined by more extensive skin
involvement and joint contractors [13–16]. However, Arkachaisiri et al. specifically studied
ANA determined by HEp-2 cellular assay in LS and did not find any significant correlations
with clinical features in LS (Fig 1A and 1I) [7].
In terms of anti-ssDNA antibodies, a growing number of reports doubt their specificity to
autoimmune diseases [17]. This is mainly due to the fact that anti-ssDNA antibodies actively
cross-react with other antigens, including phospholipids and the plasma proteins binding
them [18]. Anti-double-stranded DNA (anti-dsDNA) antibodies belong to same group of
ANA as anti-ssDNA, are common biomarkers in systemic lupus erythematosus (SLE), and
show advantageous specificity compared to anti-ssDNA (Fig 1A, III) [14,18, 19].
Once the diagnosis of LS is given, the patient is monitored regularly, and the disease activity
is assessed using an indexing system. LS comprises an inflammatory “active” phase and a later,
more fibrotic, “damage” phase. The more active phase is associated with elevations in the mod-
ified localized scleroderma skin severity index (LoSSI) and physicians’ global assessment of
disease activity (PGA-A), whereas the damage phase is associated with an elevation in the
localized scleroderma skin damage index (LoSSI) and physicians’ global assessment of disease
damage (PGA-D) [20, 21]. These indices are mainly based on the clinical manifestations of LS,
and their use requires considerable time, training and operator experience. Having reliable
biomarkers that could aid in the diagnosis, disease activity monitoring and outcome prediction
of LS would assist in current patient management and therapeutic improvements [22].
In general, specific antibody recognition can be achieved by ssDNA or ribonucleic acid
(RNA) molecules called aptamers [22]. Although the use of aptamers as diagnostic tools and
therapeutic agents has multiple benefits, only few aptamers are currently undergoing clinical
development. Post-SELEX locked nucleic acid (LNA) modification of aptamers is one of the
more promising methods to obtain short aptamers with increased biostability, structural diver-
sity, and bioactivity (Fig 1B) [23]. In case of antibody targeting, the sensitivity to chemical
composition of aptamers is well known [24]. Nevertheless, the translational role of synthetic
Antibodies in localized scleroderma detected by synthetic antigens
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DNA and RNA in LS has been limited so far by the lack of confirmed correlations with clinical
and biological role of the corresponding antibodies [24, 25].
As an emerging alternative to the rather labor extensive and expensive SELEX, computa-
tional techniques are attracting growing attention in the community [25]. In our recent work,
we used computational design for the development of novel DNA and LNA/DNA antigens
[25]. Next, we proved the efficacy of these short, LNA-labelled DNA in the detection of auto-
antibodies associated with pediatric SLE [25] a systemic autoimmune disease with multiple
manifestations that affects multiple organ systems and is notoriously associated with ANA pos-
itivity, as well as ds-DNA positivity. After determining their utility in pediatric SLE, we
decided to further expand the spectrum by applying synthetic DNA, LNA, RNA, and their
mixmers to the detection of antibodies associated with LS. In this paper we describe the syn-
thesis and the diverse tests of these new antigens, and report the results of statistical analyses of
the effects of the clinical features of patients used in this study.
Methods
Unmodified DNA/RNA strands were obtained from commercial suppliers (IDT, Exiqon).
Modified strands were prepared and characterized as described in [25].
Antibodies were provided by SSI, Denmark (anti-dsDNA, anti-β2-microglobulin monoclo-
nal antibodies), or purchased from a commercial supplier (a-CL, polyclonal antibody, Immu-
novision, Catalog No. HCL-0200; anti-dsRNA, monoclonal antibody, Kerafast, Catalog No.
ES2001). Plate coating was done following published procedure ([25]; data in S1 Appendix).
Coating efficiency was confirmed by ELISA of 31 adult SLE samples (data in S1 Appendix).
ELISA was carried out as described in [25]. Ss-DNA detected by ELISA, cut off>69, Inova
Diagnostics, San Diego, CA, USA). Cut-off value for positivity was determined for each anti-
gen as two standard deviations above the mean value for healthy controls [26–28] (Table B in
S2 Appendix). For LS samples, an additional matched group of healthy controls was applied
(Table C in S3 Appendix). The LS samples (n = 60) were derived from a well characterized
Fig 1. Current methods for the detection of a-DNA and chemical structures of nucleic acid antigens. (a) Current detection methods for anti-DNA: HEp-2 cell assay
(I), ELISA using plasmid DNA antigen (II), and the novel assay suggested in this work (using synthetic DNA/LNA/RNA; III). (b) Chemical structures of DNA, LNA and
RNA nucleotides.
https://doi.org/10.1371/journal.pone.0195381.g001
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clinical cohort, the National Registry of Childhood Onset Scleroderma housed at the Univer-
sity of Pittsburgh (Torok, PI). All sera were stored at– 20˚C until being analyzed. The personal
data of subjects was not disclosed for the project. Therefore no informed consent was needed
for the serum samples. The study was approved by Dr. Sue Beers, IRB REN18010324 /
PRO11060222.
Data analysis
For the multivariate data analysis, we used the statistical modelling framework McGLM [29],
where models are fitted under second moment assumptions (as opposed to fully specified
distributional assumptions) using a scoring algorithm [29, 30] based on quasi-likelihood and
estimating functions. Thus, a good compromise between robustness and efficiency is obtained.
For the datasets with repeated measures structures induced by the patients, we used the well-
known compound symmetry covariance structure to account for within-patient correlation.
To reduce multicollinearity, we used stepwise selection of covariates based on variance infla-
tion factors. Finally, to evaluate the fit of the models, we computed several goodness-of-fit
measures.
Results and discussion
Antigens
Antigens were designed following our recently developed procedure [25]. In brief, a TC-rich
sequence was expected to show the most effective binding to anti-DNA antibodies, and there-
fore was considered first (Table 1, D1). LNA were added to every fourth nucleotide in the
sequence (23%), resulting in L1. Both single-stranded and double-stranded variants of the
antigens were used (D1D and L1D). Next, the TC dinucleotide pair was changed to AT, giving
D2. The rationale for this step was that we wanted to maintain a hydrogen bond formed by dT
within the antigen sequence, while changing its position and the neighboring nucleotide. LNA
were also incorporated in the resulting sequence, giving L2 and L2D. We also used mixmer
sequences, D3, L3, and their duplexes, in this study. RNA variants of the DNA antigens were
included in the series as natural and partially 2’OMe/LNA (R1–R3 and their variants). The
control antigens C1 and C2 were adopted based on the literature. Rerefence C1 is a calf thymus
dsDNA and C2 is a G-quadruplex forming ssDNA [31]. These molecules were expected to
bind exclusively a-dsDNA/a-ssDNA.
The binding to autoimmune antibodies is a crucial parameter for antigens, which was first
evaluated. We applied indirect ELISA with the antigens listed in Table 1 and the antibodies
anti-dsDNA and anti-RNA as positive controls for DNA and RNA antigens, respectively; anti-
β2-microglobulin and anti-cardiolipin (anti-CL) were employed as negative controls. All anti-
bodies besides a-CL were monoclonal. The assay was carried out as follows: pre-diluted anti-
body was incubated with microtiter plates coated with corresponding antigens over 1.5 h at
37˚C, known to be equilibrium conditions [21]. After washing, secondary antibody labeled
with the histidine protein (HPr) enzyme was added and the incubation was maintained for an
additional 1.5 h at 37˚C. In the final step, 3,3’,5,5’-tetramethylbenzidine (TMB) was added and
upon its oxidation, the ultraviolet (UV) active product was detected by absorbance measure-
ment. Each sample was analyzed in duplicate with a result deviation < 3%.
Based on our results, we are able to draw three major conclusions. First, both the nucleotide
content and chemical modifications have a major impact on the antigen recognition by anti-
body, see, e.g., D1D vs L2D, and D3D vs. L3D, Table 1. Effect of nucleotide content on recog-
nition is well known for proteins and antibodies [24, 32]. However, the effect of chemical
modification has not been investigated for a-DNAs in localized scleroderma before. Second,
Antibodies in localized scleroderma detected by synthetic antigens
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RNA variants might lack specificity as most of them effectively recognize negative controls.
Third, single-strand antigens and C1–C2 show high binding to negative controls and to a-CL
in particular (Fig 2). This result is not expected for C1-C2. However, it is known that the rec-
ognition of negatively charged cardiolipin by antibodies is mainly due to electrostatic interac-
tions. Our data suggest that ssDNA, but not RNA, and large genomic CTD might interact with
antibodies due to negative charge rather than by forming bonds via nucleotide-amino acid
interactions. In turn, RNA are known to form advanced 3D structures [33]. This could con-
tribute to their recognition by a-β2-mioglobulin.
Studies of human samples
To test the antigens further, we used them in ELISA of an unmatched healthy cohort obtained
from the Odense University Hospital, Denmark (n = 60; the samples were selected randomly;
details are given in the S3 Appendix). As can be seen in Fig 2 below and in Table B in S2
Appendix, calf thymus DNA (C1) indicates 4 (5%) healthy controls as positives. This value is
4-fold lower for D1D confirming higher specificity. The reason for the higher binding by C1
Table 1. Antigen sequences and specificity to monoclonal (a-dsDNA/a-RNA, a-β2-micro-globulin), and polyclonal (a-CL) antibodies.
# Sequence, 5’-3’ ss/ds Modifi-cation Antibody binding
a-dsDNA/
a-RNA
a-β2-micro-globulin a-CL
DNA antigens
D1 5’-d(TC)10dT-3’ ss - + + ++
D1D 5’-d(TC)10dT-3’: 3’-d(AG)10dA-5’ ds - +++ - -
L1 5’-d(TCTC5MeC)5dT-3’ ss LNA - - -
L1D 5’-d(TCTC5MeC)5dT-3’: 3’-d(AG)10dA-5’ ds LNA ++ - -
D2 5’-d(AT)10dT-3’ ss - + - -
D2D 5’-d(AT)10dT-3’: 3’-d(TA)10dA-5’ ds - ++ + -
L2D 5’-d(ATATL)5dT-3’: 3’-d(TA)10dA-5’ ds LNA ++ - -
D3 5’-d(ATCG)5dA-3’ ss - + - +
D3D 5’-d(ATGC)5dA-3’: 3’-d(TACG)5dT-5’ ds - ++ - -
L3D 5’-d(ATGC5MeL)5dA-3’: 3’-d(TACG)5dT-5’ ds LNA + - -
RNA antigens
R1 5’-r(UC)10rU-3’ ss - ++ - -
R1D 5’-r(UC)10rU-3’: 3’-d(AG)10dA-5’ ds - +++ - +
L4 5’-r(UC)10rU-3’ with LNA ss LNA - + -
L4D 5’-r(UC)10rU-3’: 3’-r(AG)10rA-5’ with LNA ds LNA ++ + -
L4D-2 5’-r(UC)10rU-3’: 3’-r(AG)10rA-5’ with LNA ds LNA + + -
R2D 5’-2’OMe(UC)10rU-3’: 3’-r(AG)10rA-5’ ds 2’-OMe + ++ -
L5D 5’-2’OMe(UCUC5MeL)5rU-3’: 3’-r(AG)10rA-5’ ds 2’-OMe, LNA + ++ -
R3 5’-r(AUGC)5rA-3’ ss - ++ - -
R3D M5: 5’-r(AUGC)5rA-3’: 3’-r(UACG)5rU-5’ ds - +++ + -
L6 M5: 5’-r(AUGC5MeL)5rA-3’ ss LNA + + -
L6D M5: 5’-r(AUGC5MeL)5rA-3’: 3’-d(TACG)5dT-5’ ds LNA ++ - +
L6D-2 M5: 5’-r(AUGC5MeL)5rA-3’: 3’-r(UACG)5rU-5’ ds LNA + - -
Controls
C1 Calf thymus DNA ds - ++ + +++
C225 TTAGGGTTAGGGTTAGGGTTAGGGTTAG ss - ++ + +++
BL = LNA; C5MeC = 5-methyl cytosine LNA. See the original absorbance values in the S2 Appendix.
https://doi.org/10.1371/journal.pone.0195381.t001
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could be due to the interactions with antibodies of no relevance to LS. It is interesting that the
effect of LNA on the specificity is sequence dependent (e.g. D2D and D3D vs. L2D and L3D).
However LNA increases the number of positives in healthy controls compared to unmodified
DNA (e.g. 5 vs. 9 positive subjects detected by D2D vs. L2D, Table B in S2 Appendix).
Next, we collected a panel of human samples diagnosed with LS (see data in S3 Appendix
for clinical and demographic details concerning the subjects). We aimed to study three key
questions that have not previously been addressed: 1) the sequence specificity of LS-associated
antibodies; 2) the potential to improve analytical and clinical specificity of the a-DNA assay
using sequence-controlled antigens; and 3) the effects of the clinical features of LS subjects on
anti-nucleic acid antibodies. The LS samples were 30 active/inactive disease pairs (totalling
60 data points, two for each patient) derived from a well characterized clinical cohort, the
National Registry of Childhood Onset Scleroderma housed at the University of Pittsburgh
(Torok, PI). Disease activity was evaluated following recommended criteria [24, 25]. During
the treatment course, ANA patterns for LS patients were: 5 speckled, 2 homogenous, 1 nucleo-
lar; ANA levels detected by clinical laboratory (HEp-2 assay, [7]) were: 1:80 (n = 2; speckled
and nucleolar), 1:160 (n = 3, 2 speckled and 1 homogenous), 1:320 (n = 2, speckled and homo-
genous), 1:640 (n = 1, homogenous). At sampling, three LS subjects were ANA positive, with
the levels 1:160 (n = 2) and 1:320 (n = 1), all speckled. As a control, we used our previously
described pediatric SLE cohort (n = 27) [25].
For this study, we selected the antigens showing good specificity as evaluated in the anti-
body test, a-CL and healthy control analysis (Table 1, Fig 2), along with C1–C2. The assay was
carried out as described below, using patient samples in the primary incubation step. The
Fig 2. Analysis of new antigens in human sera. The data is presented in a modified box plot with observations outside the range
[Q1 − 1.5 IQR, Q3 + 1.5 IQR] being considered outliers and identified using asterisks. Data points for each subject are means for
three independent measurements with error< 3%. ELISA was carries out for unmatched healthy controls, n = 60 (see Methods
for details). For absorbance values, see data in S2 Appendix.
https://doi.org/10.1371/journal.pone.0195381.g002
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results of the ELISA testing are shown in Fig 3. For LS, we analyzed IgG and IgM in separate
ELISA tests. Anti-DNA of the IgG isotype is the most common in LS [13–16]. Nevertheless,
we included IgM a-DNA and IgM a-RNA in this study to evaluate the potential effect of LNA
and DNA/RNA sequences on recognition of a different class of anti-DNA.
In the IgG profile (Fig 3A), the highest number of positive samples is shown for the antigens
D1D, D2D, and the control C2, whereas the mixmer D3D shows nearly no positive signals.
Similar to SLE, the polyclonal antibodies to nucleic acids in LS are indeed sequence specific,
and most effectively recognize single- and double-stranded [dT] DNA. Interestingly, the con-
trol C1 exhibits less binding than other antigens, e.g., vs. C2, which displays high binding.
Another striking finding is that the incorporation of LNA monomers in the 21-mer anti-
gens has a highly dramatic influence on antibody recognition. For D1D and D2D, the signal
decreases 4–8-fold upon LNA incorporation. However, for D3D and L3D, the effect of LNA
on binding levels is the opposite.
For IgM, the binding levels differed from IgG (Fig 3B compared to Fig 3A; data in S2
Appendix). D1D still showed the highest signal; however, the influence of LNA on the anti-
body levels changed. Specifically, the signal decreased for L1D compared to D1D, and
increased for L2D–L3D vs. LNA-free D2D and D3D. Both C1 and C2 exhibited a low signal.
For RNA antigens, the difference in binding levels was as dramatic as in the IgG test.
We compared the binding levels for LS across novel antigens with another disease, pSLE
(n = 27) (see data in S3 Appendix for subject information). Compared to LS, pSLE have higher
binding levels for all antigens, with a lower sensitivity to a particular sequence. This could be
caused by high disease activity in the pSLE cohort (Table A in S3 Appendix). Nevertheless, the
influence of LNA was similar for LS and pSLE: binding to L1D–L2D decreased compared to
the DNA analogues D1D–D2D, and increased for the mixmer L3D vs. DNA D3D. Lower
binding to G-quadruplex C2 was observed and a high level of antibodies in pSLE recognized
CTD C1.
Fig 3. Results of IgG (A) and IgM (B) ELISA assay for LS subjects (n = 30) using DNA and LNA/DNA antigens. Both figures are modified box plots, where
observations outside the range [Q1 − 1.5 IQR, Q3 + 1.5 IQR] are considered outliers and identified using asterisks. Data points for each subject are means for three
independent measurements with error< 3%. For absorbance values, see data in S2 Appendix.
https://doi.org/10.1371/journal.pone.0195381.g003
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Using D1D, 30% (n = 18) LS samples were positive. This value was 6-fold higher than for
ANA determined by clinical laboratory (5% positive), and 1.5-fold higher than AHA (20% pos-
itive; Table A in S3 Appendix). Notably, in the control assays C1-C2 no positive samples were
detected (Table C in S2 Appendix).
Statistical analyses
For the multivariate data analysis, we adopted an extension of generalized linear models called
multivariate covariance generalized linear models (McGLMs) as implemented in the R [27]
package mcglm [28], which is a very general and comprehensive framework proposed by
Bonat and Jørgensen [29]. In this framework, the models are fitted using an estimating func-
tion approach based on second moment assumptions only, which provides some robustness
against misspecification of the models. In both models, the variables D1D, L1D, D2D, L2D,
D3D, L3D, C1, and C2 serve as response variables, while the variables Time in Treatment,
mLoSSI, LoSSI, PGAACT, and PGADAMG serve as covariates for all response variables. In
order to reduce multicollinearity, we used stepwise selection of covariates based on variance
inflation factors. Table Q in S4 Appendix was used to assess multicollinearity among covariates
in the final models. In the model fitted to the IgG LS dataset, we used the log link function and
the Tweedie variance function (where the power parameter is estimated) for the response vari-
ables D1D, L2D, D3D, and L3D, and the identity link function and the constant variance func-
tion for the response variables L1D, D2D, C1, and C2. In the model fitted to the IgM LS
dataset, we used the log link function and the Tweedie variance function (where the power
parameter is estimated) for the response variables D1D, L1D, L2D, D3D, L3D, C1, and C2,
and the identity link function and the constant variance function for the response variable
D2D. Both datasets have a repeated measures structure which may induce some correlation
between observations on the same patient. Thus, it seemed reasonable to account for within-
patient correlation induced by the repeated measurements using the well-known compound
symmetry covariance structure, defined by a linear combination of an identity matrix and a
matrix of 1s. However, since the repeated measures structure was not significant for any
response variable in the model fitted to the IgG LS dataset, we assumed independent observa-
tions. In the model fitted to the IgM dataset, the repeated measures structure was significant
for the response variable D1D only, but since it had no impact on the final results in terms of
significance of the covariates, we assumed again independent observations. Finally, to evaluate
the fit of the models, we computed several goodness-of-fit measures. In general, we observe
that the multivariate models provide a better fit to the data than the univariate models. More-
over, to obtain a more parsimonious model for the IgG LS dataset, we used a stepwise regres-
sion procedure with Bayesian information criterion (BIC).
The main question we would like to address in this work is if there are specific polyclonal
antibodies where the level of binding correlates with other disease activity measures or corre-
lates with several disease activity measures used together. To answer on this, we studied the
effects of clinical features of the LS subjects on the detected antibody titers. We use the models
to make inferences about the effects of clinical features from IgG and IgM datasets. In particu-
lar we focused on effects of disease indices of activity on antibodies to new antigens: mLoSSI
and PGAACT, and indices of disease damage: LoSDI and PGADAMG. Time in treatment
(treatment duration to time of blood sample) was included as well.
According to our analysis, IgG and IgM datasets varied (Table 2 and data in S4 Appendix).
For IgG, mLoSSI, which is characteristics of active LS, had significant effect on G-quadruplex
forming C2 [31]. The localized scleroderma skin damage index LoSDI, but not PGADAMG,
had an effect on several biomarkers: a-D1D, a-L2D, a-L3D, and C1. This indicates a potential
Antibodies in localized scleroderma detected by synthetic antigens
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linking for a-DNA to the biological status of disease state in LS which has not been reported
before. On the contrary, PGADAMG (disease damage index) reflects cumulative disease but
not necessarily biologic activity [9, 20]. Therefore the absence of a correlation for the PGA-
DAMG with the a-DNA additionally supports the hypothesis on their biological role in LS.
Interestingly, the model suggests that LoSDI does not have an effect on the antibodies to con-
trol C2. It is also interesting that the effects changed for the analogues a-D1D vs. a-L1D, a-
D2D vs. a-L2D, and a-D3D vs. a-L3D.
Time in treatment had an effect exclusively on a-D1D and a-D3D (Table 2). This is an inter-
esting observation given the complete lack of this effect in the antibodies to controls and other
synthetic antigens used in this work. No other tested parameters showed significant effects on
the antibodies to either synthetic antigens or controls (data in S4 Appendix). As to IgM, LoSDI
and time in treatment had an effect on most variables including C1-C2; little to no difference
was seen for LNA vs. DNA analogues (data in S4 Appendix).
Finally, we compared the quantitative characteristics of our tests in the detection of anti-
bodies related to LS with the results for novel antigens. The results of ANA and anti-ssDNA
testing in LS are typically reported as either the dilution of serum that tests positive or the
degree of positivity measured by the testing procedure (staining pattern) [34, 35]. Having per-
formed a sera dilution study, we concluded that the novel antigens show up to 10-fold higher
analytical sensitivity over the control C1 and commercial anti-ssDNA kit (data in S3 Appen-
dix), most likely due to the high purity (> 90%) of the former.
Conclusions
In conclusion, we have designed and tested new synthetic nucleic acids as antigens for the
diagnosis and characterization of localized scleroderma (LS). Besides showing higher analytical
specificity for the detection of LS-associated antibodies, our work implies biological relevance
of these biomarkers in the LS. According to our results, synthetic TC-rich DNA is the most
efficient antigen for the detection of active LS disease, albeit as a double-strand variant only.
Several other antigens also show effects of clinical parameters among LS patients on IgG anti-
body levels. This is in contrast to the rather poor performance of the DNA antigens, especially
when studying healthy controls.
Our studies suggest that single-stranded DNA and RNA impurities could contribute to the
false positive results when detecting antibodies to dsDNA. Therefore, their presence in DNA
antigens has to be controlled with care. Moreover, LNA is often applied in aptamer develop-
ment. Our work shows that LNA incorporation affects antibody binding and therefore
requires careful controls.
Table 2. Results of statistical analyses of IgG ELISA data. Effects at a significance level of 0.05 (p<0.05) are shown in red.
Biomarker/
Clinical features
Disease activity indexes Disease damage indexes Time in treatment
mLoSSI PGAACT LoSDI PGADAMG
a-D1D
a-L1D
a-D2D
a-L2D
a-D3D
a-L3D
C1
C2
https://doi.org/10.1371/journal.pone.0195381.t002
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Based on our results, we believe that rationally designed oligonucleotides could aid in the
discovery of a new generation of biomarkers for the specific diagnosis and point-of-care moni-
toring of LS and other autoimmune diseases that involve the development of antibodies to
nucleic acids. This includes, but not limited to, systemic lupus erythematosus and autoimmune
hepatitis [17, 36, 37].
Supporting information
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